EGFR (D761Y)

EGFR · Variant type: point · HGVS: p.D761Y

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	100.0%	0.0%	97.24
2	Dacomitinib	99.9%	0.1%	97.99
3	Ibrutinib	99.8%	0.2%	94.74
4	Mobocertinib	99.7%	0.3%	97.22
5	Lazertinib	99.7%	0.3%	97.47
6	Neratinib	99.7%	0.3%	93.18
7	Canertinib	99.7%	0.3%	96.49
8	Lapatinib	99.6%	0.4%	99.25
9	Erlotinib	99.5%	0.5%	99.75
10	Afatinib	99.3%	0.7%	98.50
11	Vandetanib	99.2%	0.8%	95.74
12	Pralsetinib	98.9%	1.1%	93.43
13	Gefitinib	98.8%	1.2%	99.25
14	Zanubrutinib	98.2%	1.8%	98.24
15	Fostamatinib	97.6%	2.4%	96.74
16	Defactinib	97.5%	2.5%	92.68
17	Bosutinib	96.7%	3.3%	87.22
18	Brigatinib	96.4%	3.6%	82.96
19	Dasatinib	87.0%	13.1%	87.97
20	Pacritinib	74.5%	25.5%	88.64
21	Alpelisib	70.5%	29.5%	97.22
22	Ponatinib	60.5%	39.5%	78.23
23	Gilteritinib	57.3%	42.7%	88.97
24	Pirtobrutinib	49.7%	50.3%	99.49
25	Alectinib	47.8%	52.2%	95.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	100.0%	99.1%	+0.9%
Dacomitinib	99.9%	99.8%	+0.1%
Ibrutinib	99.8%	99.3%	+0.5%
Mobocertinib	99.7%	100.0%	-0.3%
Lazertinib	99.7%	100.0%	-0.3%
Neratinib	99.7%	100.0%	-0.3%
Canertinib	99.7%	98.4%	+1.2%
Lapatinib	99.6%	99.2%	+0.4%
Erlotinib	99.5%	99.4%	+0.0%
Afatinib	99.3%	100.0%	-0.6%
Vandetanib	99.2%	99.3%	-0.1%
Pralsetinib	98.9%	99.1%	-0.2%
Gefitinib	98.8%	99.9%	-1.1%
Zanubrutinib	98.2%	88.2%	+10.0%
Fostamatinib	97.6%	97.8%	-0.2%
Defactinib	97.5%	94.6%	+2.9%
Bosutinib	96.7%	99.3%	-2.5%
Brigatinib	96.4%	98.5%	-2.1%
Dasatinib	87.0%	97.9%	-11.0%
Pacritinib	74.5%	—	—
Alpelisib	70.5%	—	—
Ponatinib	60.5%	—	—
Gilteritinib	57.3%	91.0%	-33.8%
Pirtobrutinib	49.7%	—	—
Alectinib	47.8%	—	—

Cancer	Organ	Source
other_lung	Lung	ref
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 34.4ms